Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction

Kuck, Karl‐Heinz; Dorian, Paul

doi:10.1016/j.accreview.2005.02.021

Cited by 212 publications

(303 citation statements)

References 0 publications

Supporting

Mentioning

272

Contrasting

Unclassified

Order By: Relevance

“…The question of whether patients with recent MI could benefit from early ICD implantation was addressed in DINAMIT (Defibrillator in Acute Myocardial Infarction Trial) 16. The patients enrolled in this study had recent MI (6–40 days), reduced LVEF (⩽35%), and impaired cardiac autonomic function.…”

Section: Primary Preventionmentioning

confidence: 99%

Primary and secondary prevention of sudden cardiac death: who should get an ICD?

Santini

Lavalle

Ricci

2007

Heart

View full text Add to dashboard Cite

Section: Primary Preventionmentioning

confidence: 99%

Primary and secondary prevention of sudden cardiac death: who should get an ICD?

Santini

Lavalle

Ricci

2007

Heart

View full text Add to dashboard Cite

“…Prior investigations evaluating the role of EF in the post-MI population have mostly dealt with those having a moderate or severely depressed EF 10 19 20. Of note, studies involving post-MI patients with preserved or mildly reduced EF (such as the PEACE population) are sparse; thus, our findings are particularly clinically relevant as they provide novel insight into the cardiovascular outcomes of this subset of infarct survivors.…”

Section: Discussionmentioning

confidence: 86%

Preserved or slightly depressed ejection fraction and outcomes after myocardial infarction

Badheka

Rathod

Bharadwaj

et al. 2011

Postgraduate Medical Journal

View full text Add to dashboard Cite

BACKGROUND Left ventricular ejection fraction (EF) in post-myocardial infarction (MI) patients is a strong predictor of adverse cardiovascular events. Although resting EF as measured by transthoracic echocardiography (TTE), contrast ventriculography (CNV), and radionuclide angiography (RNA) exhibit high correlation, there is only modest agreement between these modalities. This study sought to explore whether modality of EF assessment influences prognostication of post-MI patients with normal or slightly reduced EF. METHODS AND RESULTS The National Heart, Lung, and Blood Institute (NHLBI) limited access dataset of the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial (1996-2003, n=8290) comparing trandolapril versus placebo was used. The cohort was partitioned into TTE (n=2582), RNA (n=816), and CNV (n=1155) groups based on modality of EF assessment. EF was a significant predictor of cardiovascular mortality (HR 0.97, 95% CI 0.95 to 0.98; p<0.005) and all cause mortality (HR 0.98, 95% CI 0.97 to 0.99; p=0.0002) on multivariate analysis in this population with preserved or mildly depressed EF. Although CNV, TTE, and RNA groups differed significantly in terms of baseline variables, no appreciable differences were noted between RNA (HR 1.13, 95% CI 0.85 to 1.50; ns) and CNV (HR 1.13, 95% CI 0.99 to 1.27; ns) groups, compared with TTE for all cause mortality. Similarly, no significant differences were observed for cardiovascular mortality between RNA (HR 1.23, 95% CI 0.82 to 1.84; p=0.31) and CNV (HR 1.14, 95% CI 0.78 to 1.67, p=0.49) versus TTE. CONCLUSION EF is a significant predictor of all-cause mortality and cardiovascular mortality in patients with preserved or mildly depressed EF. Modalities of EF measurement are interchangeable and do not play a significant role in prognostication in a post-MI population.

show abstract

“…In this context, it is relevant to note that in the EPHESUS trial, early treatment with the mineralocorticoid receptor antagonist eplerenone was associated with reduction in the risk of sudden death in patients with heart failure or impaired LV function after AMI 29. Further, the DINAMIT trial,30 which did not see a benefit from ICD therapy post-MI, did not randomise patients on the basis of history of resuscitated CA. Further, DINAMIT recruited patients between 6 and 40 days post-MI and possibly missed the time window of high risk associated with resuscitated CA.…”

Section: Discussionmentioning

confidence: 99%

Resuscitated cardiac arrest and prognosis following myocardial infarction

Alahmar

Nelson

Snell

et al. 2014

Heart

View full text Add to dashboard Cite

show abstract

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction

Cited by 212 publications

References 0 publications

Primary and secondary prevention of sudden cardiac death: who should get an ICD?

Primary and secondary prevention of sudden cardiac death: who should get an ICD?

Preserved or slightly depressed ejection fraction and outcomes after myocardial infarction

Resuscitated cardiac arrest and prognosis following myocardial infarction

Contact Info

Product

Resources

About